# rheumatoid arthritis - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 1
- Task type: DISEASE-STATE
- Tissue / sample source: synovial tissue
- Comparison or endpoint: rheumatoid arthritis versus normal control
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: d868ce3efb219458b8d5ddb7b123eef3f2b718852ba0ede74f2a02e9181db293
- Response HTTP status: 200
- Prompt tokens: 4077
- Completion tokens: 19794
- Reasoning tokens: 
- Total tokens: 23871
- API requests reported: 
- Elapsed seconds: 203.695
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
# 1. Overall biological interpretation

The supplied differential expression table contains only genes with negative log2 fold changes; no upregulated genes are provided. In this rheumatoid arthritis (RA) versus normal synovial tissue comparison, the strongest transcriptomic signal is therefore a coordinate loss of many normally expressed resident-tissue gene programs rather than a gain of inflammatory or immune effector genes.

Interpreted as a set, the downregulated genes point to:

- **Disruption of resident synovial cell architecture**, including cell–cell junctions, apical-basal or planar cell polarity, and Wnt-related regulatory machinery.
- **Loss or altered expression of primary cilia / centrosomal / cytoskeletal components**, which are important for fibroblast mechanosensing, signaling, and tissue homeostasis.
- **Reduced expression of nuclear regulators**, including chromatin-related proteins, zinc-finger transcription factors, RNA-processing factors, and mRNA decay / translation regulators.
- **Loss of a set of tissue-restricted or unusual marker genes**, including mucins, cadherin-related proteins, and some neuronal/tissue-specific markers. These are not typical canonical synovial lining genes and may reflect a genuine but poorly understood resident-cell identity program, or they may indicate contamination / cell-composition differences between RA and normal synovial samples.

Because every gene is downregulated, the current data cannot support conclusions about activated inflammatory programs in RA. The most defensible interpretation is that RA synovial tissue undergoes a substantial remodeling of resident cell transcriptional identity, with the strongest signals involving structural, polarity, ciliary, and nuclear regulatory programs.

---

# 2. Core biological programs

Below are four major programs, prioritized for biological coherence and supported by multiple genes in the input table.

## Program 1: Loss of cell–cell junction, polarity, and Wnt-regulatory program

**Direction or prognostic association:** Downregulated in RA vs normal.

**Major supporting genes:**  
`APC2`, `ARVCF`, `SCRIB`, `CDHR5`, `GJC2`

**Most appropriate standard pathway:**  
- KEGG: `hsa04520` Adherens junction  
- KEGG: `hsa04310` Wnt signaling pathway  
- GO: `GO:0005913` cell–cell adherens junction; `GO:0001736` planar cell polarity

**Biological interpretation:**  
`APC2` encodes an adenomatous polyposis coli-like tumour suppressor that negatively regulates canonical Wnt/β-catenin signaling. `SCRIB` is a basolateral cell polarity scaffold involved in planar cell polarity and epithelial/mesenchymal organization. `ARVCF` is an armadillo-repeat protein that interacts with p120-catenin at adherens junctions. `CDHR5` is a cadherin-related protein, and `GJC2` encodes a gap-junction connexin. The coordinated downregulation of these genes suggests that RA synovial tissue loses part of its normal junctional / polarity architecture. Because these genes also intersect with Wnt signaling, their loss could contribute to altered synovial fibroblast proliferation, migration, or tissue organization.

**Strength of evidence:** Moderate. Multiple independent genes with highly significant statistics support the program. The limitation is that these genes are not synovial-specific, and the exact cell type in which they are downregulated is not known from bulk tissue data.

**Major limitations:** No direct functional Wnt or junction activity was measured. The connection to RA synovial fibroblast behavior is inferred from pathway annotation and prior disease biology, not directly demonstrated here.

---

## Program 2: Loss of primary cilia / centrosomal and cytoskeletal machinery

**Direction or prognostic association:** Downregulated in RA vs normal.

**Major supporting genes:**  
`CROCC`, `CROCC2`, `CROCCP2`, `CCDC9`, `CCDC154`, `INF2`, `PPP1R12C`, `ACAP3`, `PLEKHH3`, `TSNARE1`

**Most appropriate standard pathway:**  
- GO: `GO:0060271` cilium assembly  
- GO: `GO:0005814` centrosome  
- GO: `GO:0030036` actin cytoskeleton organization  
- Reactome: Rho GTPase cycle

**Biological interpretation:**  
`CROCC` and its related loci encode rootletin, a core component of the ciliary rootlet, while `CCDC9` and `CCDC154` are coiled-coil proteins with centrosome/cilia annotations. `INF2` is an inverted formin involved in actin polymerization, mitochondrial dynamics, and cytoskeletal organization. `PPP1R12C` is a myosin phosphatase regulatory subunit, and `ACAP3` / `PLEKHH3` are GTPase regulators. Together, these genes support a coordinated downregulation of primary cilia–associated and cytoskeletal signaling modules. Primary cilia are important mechanosensors in fibroblasts and can modulate Wnt and Hedgehog signaling, so their loss could contribute to abnormal synovial fibroblast behavior in RA.

**Strength of evidence:** Moderate. The ciliary/centrosomal grouping is supported by multiple genes. The limitation is that several supporting genes are uncharacterized or pseudogenes (`CROCCP2`), and no functional cilia readout exists in the current dataset.

**Major limitations:** Bulk tissue cannot establish whether cilia numbers, cilia length, or ciliary signaling are actually altered. The role of primary cilia specifically in RA synovial fibroblasts remains an extrapolation.

---

## Program 3: Reduced nuclear gene-expression regulatory machinery: chromatin, transcription, RNA processing, and translation control

**Direction or prognostic association:** Downregulated in RA vs normal.

**Major supporting genes:**  
`CBX7`, `PAGR1`, `TNRC18`, `HDGFL2`, `ZNF316`, `ZNF219`, `ZNF444`, `ZNF580`, `SCAF1`, `CNOT12`, `GIGYF1`, `ELOA3`

**Most appropriate standard pathway:**  
- GO: `GO:0006325` chromatin organization  
- GO: `GO:0006396` RNA processing  
- GO: `GO:0000184` nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay  
- Reactome: RNA Polymerase II Transcription / mRNA decay

**Biological interpretation:**  
This group contains multiple zinc-finger transcriptional regulators, the chromobox protein `CBX7` (a Polycomb repressive complex subunit), `PAGR1` (a component of the PTIP/PAXIP1 chromatin-associated complex), `SCAF1` (an RNA polymerase II associated splicing factor), `CNOT12` (a CCR4-NOT deadenylase subunit), `GIGYF1` (a 4EHP-associated translational repressor), and `ELOA3` (an elongin A-related transcription elongation factor). The coordinated downregulation of these genes suggests that RA synovial tissue loses part of its normal nuclear RNA-expression regulatory capacity. This could reflect a shift from a differentiated resident-cell state toward a “dedifferentiated” or altered fibroblast phenotype, although it could also reflect dilution of resident cells by immune infiltration.

**Strength of evidence:** Moderate-to-good for the existence of a statistically coordinated set of genes, but weak for specificity. The genes are broad and functionally heterogeneous, so this program is less mechanistically crisp than Programs 1 and 2.

**Major limitations:** This is a broad gene-expression regulatory program and could be a nonspecific consequence of tissue composition changes. Many zinc-finger genes and noncoding loci may also be co-regulated by genomic adjacency or chromatin domains rather than by a shared disease mechanism.

---

## Program 4: Loss of tissue-restricted / mucin-related and ectopic marker genes — possible resident-cell identity or composition sentinel

**Direction or prognostic association:** Downregulated in RA vs normal.

**Major supporting genes:**  
`MUC5B`, `MUC6`, `MUC12`, `CDHR5`, `DRD4`, `GJC2`, `CYP2W1`, `GRIFIN`, `CEMP1`, `SCART1`

**Most appropriate standard pathway:**  
- KEGG: `hsa00512` Mucin-type O-glycan biosynthesis (for the mucin subset)  
- No single canonical pathway captures the entire group; this module is best viewed as a set of tissue-restricted markers rather than a conventional signaling pathway.

**Biological interpretation:**  
This group is striking because several genes are not classic synovial genes. `MUC5B`, `MUC6`, and `MUC12` are mucins, `CDHR5` is a brush-border cadherin, `DRD4` is a dopamine receptor, `CYP2W1` is a cytochrome P450 mainly studied in colorectal cancer, `GRIFIN` is a lens-enriched protein, `CEMP1` is associated with cementum, and `SCART1` can mark a T-cell subset. Their coordinate downregulation in RA could mean that a specific resident cell population in normal synovium expresses unexpected tissue-restricted genes and is lost or transcriptionally altered in RA. Alternatively, these genes may come from contaminating adjacent normal tissue included in “normal synovial” samples, and RA samples may contain less of that contaminating tissue. This is a critical composition/confounding issue that must be resolved before interpreting this group functionally.

**Strength of evidence:** High statistical confidence for differential expression, but low biological confidence for any specific disease mechanism. The main value of this program is as a **warning signal** for tissue composition or sample-origin effects.

**Major limitations:** The genes are not known synovial markers. Without spatial transcriptomics or sorted cell populations, it is impossible to determine whether these genes are genuinely expressed in synovial lining cells or whether they reflect sample contamination / anatomical variation.

---

# 3. Key genes and interaction modules

The following are the most informative genes or gene modules from the current dataset.

## 3.1 `APC2` — Wnt regulator and junctional program

- **Direction:** Downregulated (`log2FC = -3.018`).
- **Potential role:** Negative regulator of canonical Wnt/β-catenin signaling; may also participate in cell polarity.
- **Gene-gene relationships:** `APC2` is a pathway co-member with `SCRIB` and `ARVCF` in adherens-junction / Wnt / planar-cell-polarity networks. There is no evidence from the current dataset of a direct physical interaction.

## 3.2 `SCRIB` / `ARVCF` module — polarity and junctional scaffolds

- **Direction:** `SCRIB` downregulated (`log2FC = -3.235`); `ARVCF` downregulated (`log2FC = -3.462`).
- **Potential role:** `SCRIB` organizes apical-basal polarity and planar cell polarity; `ARVCF` binds p120-catenin at cadherin-based junctions.
- **Gene-gene relationships:** They are best described as **pathway co-members** in cell-polarity and adherens-junction regulation. Direct physical interaction between `SCRIB` and `ARVCF` is not established by this dataset.

## 3.3 `CROCC` / `CCDC9` / `CCDC154` module — centrosome and ciliary rootlet

- **Direction:** `CROCC` downregulated (`log2FC = -3.883`); `CROCC2` downregulated (`log2FC = -4.994`); `CCDC9` downregulated (`log2FC = -3.019`); `CCDC154` downregulated (`log2FC = -3.299`).
- **Potential role:** `CROCC` encodes rootletin, a major ciliary rootlet component. `CCDC9` and `CCDC154` have centrosome/cilia-related annotations. This module supports the idea that primary cilia or centrosomal function is reduced in RA synovial tissue.
- **Gene-gene relationships:** **Co-expression / pathway co-membership** inferred from shared centrosome/cilia involvement. Direct physical interactions among these proteins are not demonstrated here.

## 3.4 `CBX7` / `PAGR1` module — chromatin regulatory axis

- **Direction:** `CBX7` downregulated (`log2FC = -2.413`); `PAGR1` downregulated (`log2FC = -2.341`).
- **Potential role:** `CBX7` is a Polycomb repressive complex 1 subunit and can regulate senescence and gene silencing. `PAGR1` associates with the PTIP complex, important for H3K4 methylation and DNA-damage responses.
- **Gene-gene relationships:** They are **co-members of a broader chromatin regulatory network**, but there is no evidence here that they directly interact physically with each other.

## 3.5 `GIGYF1` / `CNOT12` module — post-transcriptional and mRNA decay machinery

- **Direction:** `GIGYF1` downregulated (`log2FC = -2.876`); `CNOT12` downregulated (`log2FC = -2.942`).
- **Potential role:** `GIGYF1` is a translational repressor that cooperates with 4EHP and ZFP36 proteins to regulate mRNAs; `CNOT12` is a CCR4-NOT deadenylase subunit involved in mRNA decay.
- **Gene-gene relationships:** They are **pathway co-members** in mRNA translational silencing / decay. Direct physical interaction is not yet established by the current data.

## 3.6 `D2HGDH` — metabolic–epigenetic candidate

- **Direction:** Downregulated (`log2FC = -2.764`).
- **Potential role:** `D2HGDH` encodes D-2-hydroxyglutarate dehydrogenase, which metabolizes D-2-hydroxyglutarate (D-2-HG). Loss of `D2HGDH` could lead to D-2-HG accumulation, which can inhibit α-ketoglutarate-dependent dioxygenases, including histone demethylases. This is an attractive but highly speculative metabolic–epigenetic link.
- **Gene-gene relationships:** Indirect or putative. The connection to chromatin genes like `PAGR1` and `CBX7` is not direct.

## 3.7 `SH2B1` — JAK/STAT adaptor

- **Direction:** Downregulated (`log2FC = -2.279`).
- **Potential role:** `SH2B1` is an adaptor protein that directly binds JAK2 and enhances JAK2 signaling. Its downregulation in RA synovium is interesting because JAK/STAT signaling is important in RA, but the functional direction is not obvious from gene expression alone.
- **Gene-gene relationships:** Direct physical interaction with JAK2 is supported in the published literature. However, this does not mean the current dataset demonstrates altered JAK2 activity.

## 3.8 `MUC5B` — composition sentinel

- **Direction:** Downregulated (`log2FC = -4.426`).
- **Potential role:** `MUC5B` is a gel-forming mucin, not a classical synovial fibroblast gene. Its very strong downregulation is biologically suspicious.
- **Gene-gene relationships:** `MUC5B`, `MUC6`, and `MUC12` are **pathway co-members** of mucin-type O-glycosylation / secreted mucins, but this likely reflects tissue-origin or composition differences more than a shared RA-specific regulatory mechanism.

---

# 4. Validation priorities

## 4.1 Confounding / composition check: cell-type origin and tissue composition

**Why it deserves prioritization:**  
All differentially expressed genes are downregulated, and several are tissue-restricted genes not normally associated with synovium. Before interpreting these as RA-specific changes, the field needs to know whether they reflect cell-composition changes, contamination, or genuine per-cell transcriptional loss.

**Evidence from dataset:**  
Strong downregulation of `MUC5B`, `MUC6`, `MUC12`, `DRD4`, `CYP2W1`, `GRIFIN`, and related markers.

**External evidence:**  
Most of these genes are not established synovial markers, which argues that composition or anatomical contamination should be excluded.

**Next step:**  
Perform single-cell RNA-seq or spatial transcriptomics on RA and normal synovium; validate expression of `APC2`, `CROCC`, `MUC5B`, and `DRD4` in defined cell populations. Use cell-type deconvolution from bulk RNA-seq as a complementary check.

**Evidence level:**  
Exploratory hypothesis.

---

## 4.2 Mechanistic hypothesis: primary cilia / centrosomal and cell-polarity loss in RA synovial fibroblasts

**Why it deserves prioritization:**  
The coordinated downregulation of ciliary rootletin and centrosome-related genes is one of the strongest and most specific signals in the dataset.

**Evidence from dataset:**  
`CROCC`, `CROCC2`, `CCDC9`, `CCDC154`, `INF2`, and `PPP1R12C` are all downregulated.

**External evidence:**  
Primary cilia regulate fibroblast mechanosensing, Hedgehog signaling, and Wnt signaling. Ciliary dysfunction can alter cell proliferation and tissue remodeling. However, direct RA-specific cilia data are limited.

**Next step:**  
Culture RA and normal synovial fibroblasts, quantify primary cilia frequency and length, and test whether inflammatory cytokines such as TNF-α or IL-1β downregulate `CROCC` and `CCDC9` in vitro.

**Evidence level:**  
Exploratory hypothesis.

---

## 4.3 Interaction / network hypothesis: `D2HGDH` loss and D-2-HG-dependent epigenetic dysregulation

**Why it deserves prioritization:**  
This hypothesis links a metabolic observation to chromatin regulation and could explain broader transcriptional changes.

**Evidence from dataset:**  
`D2HGDH` is strongly downregulated; multiple chromatin-related genes (`CBX7`, `PAGR1`, `ZNF316`, `ZNF219`) are also downregulated.

**External evidence:**  
Loss of `D2HGDH` is known to cause D-2-hydroxyglutaric aciduria. D-2-HG is an oncometabolite that inhibits α-ketoglutarate-dependent dioxygenases, including Jumonji histone demethylases and TET enzymes.

**Next step:**  
Measure D-2-HG levels in RA versus normal synovial tissue or synovial fluid; test whether D-2-HG treatment of synovial fibroblasts alters histone methylation or inflammatory gene expression.

**Evidence level:**  
Exploratory hypothesis.

---

## 4.4 Therapeutic target hypothesis: APC2 / Wnt–β-catenin signaling in synovial fibroblasts

**Why it deserves prioritization:**  
`APC2` is a well-known negative regulator of Wnt/β-catenin signaling, a pathway implicated in fibroblast proliferation, fibrosis, and joint destruction.

**Evidence from dataset:**  
`APC2` is strongly downregulated, together with polarity gene `SCRIB` and junctional gene `ARVCF`.

**External evidence:**  
Wnt/β-catenin activation is reported in RA synovium and contributes to synovial hyperplasia and bone erosion. However, `APC2` downregulation alone is not sufficient to prove Wnt activation.

**Next step:**  
Measure β-catenin protein levels and Wnt reporter activity in RA synovial fibroblasts, then test whether restoring `APC2` expression reduces proliferation, migration, or pro-inflammatory gene expression.

**Evidence level:**  
Exploratory hypothesis.

---

## 4.5 Biomarker direction: downregulated resident-tissue gene score

**Why it deserves prioritization:**  
A reproducible decrease in resident synovial structural genes might serve as a quantitative measure of synovial tissue remodeling or disease-related loss of normal lining phenotype.

**Evidence from dataset:**  
`APC2`, `CROCC`, `SCRIB`, and `MUC5B` show very strong fold changes and very low FDR values.

**External evidence:**  
No established biomarker panel currently uses these genes. This is therefore an early-stage biomarker concept.

**Next step:**  
Validate expression of a small panel (`APC2`, `CROCC`, `SCRIB`, `MUC5B`) by qPCR or NanoString in an independent cohort of RA and normal synovial samples; correlate with histological inflammation, disease activity, or treatment status.

**Evidence level:**  
Exploratory hypothesis.

---

# 5. Evidence grounding

The interpretations above rely on several distinct evidence types:

- **Direct evidence from the input dataset:** Differential expression statistics, effect sizes, and FDR values. These are the primary and most reliable evidence.
- **Pathway / ontology evidence:** Assignments of genes to GO, Reactome, or KEGG pathways. This evidence is external and depends on existing annotation quality.
- **Protein interaction or regulatory evidence:** Literature-supported relationships such as `SH2B1`–JAK2 or `GIGYF1`–4EHP. These are informative but are not derived from the current dataset.
- **Disease-association evidence:** RA literature linking Wnt signaling, synovial fibroblast activation, and inflammation. This is useful but does not confirm that the specific genes in this list drive RA.
- **Expression / tissue-specific evidence:** Known expression patterns of genes like `MUC5B`, `DRD4`, `CYP2W1`, and `GRIFIN` argue that some findings may reflect tissue composition or contamination.
- **Genetic / clinical evidence:** For example, `D2HGDH` mutations cause D-2-HG accumulation, and `MUC5B` variants are linked to interstitial lung disease. These provide indirect support for biological plausibility but not direct evidence for RA synovial pathology.

**Independence of evidence:**  
The input statistics are direct. The pathway and literature evidence are external but not fully independent because they often annotate the same genes. Therefore, pathway enrichment or literature support should not be treated as independent confirmation of the differential expression results.

---

# 6. Limitations and alternative explanations

## 6.1 Tissue / cell-composition differences

RA synovium is highly infiltrated by immune cells and shows synovial lining hyperplasia. Bulk transcriptomic downregulation of resident-cell genes can arise from cell dilution even if per-cell expression is unchanged. The presence of mucins and other tissue-restricted genes suggests possible contamination or anatomical variation in normal samples.  
**How to investigate:** single-cell and spatial transcriptomics; cell-type deconvolution; immunohistochemistry for key markers.

## 6.2 Absence of upregulated genes

The input table contains no upregulated genes. This is unusual for RA, which typically shows strong upregulation of inflammatory and immune genes. It may mean that the provided table is a filtered subset, or that the bioinformatic pipeline emphasized downregulated genes, or that normalization / platform effects obscured inflammatory signals. This prevents a full biological interpretation of RA pathophysiology.

## 6.3 Treatment exposure and disease stage

RA patients included in such studies are often treated with DMARDs, steroids, or biologics, which can profoundly alter synovial gene expression. Normal controls are typically untreated. Thus, the observed downregulation may reflect drug effects or chronic disease duration rather than intrinsic disease biology.

## 6.4 Genomic locus and noncoding annotation issues

Many significant features are noncoding: `LOC` genes, antisense RNAs, microRNAs, snoRNAs, pseudogenes, and rRNA-related sequences. Some may be genuine regulatory elements, but others may be artifacts of alignment, rRNA depletion, or ambiguous annotation. In addition, genes in the same genomic locus, such as `DMPK`, `SIX5`, and `DM1-AS`, may be co-downregulated because of a single shared regulatory region rather than independent biological pathways.

## 6.5 Association-versus-causation ambiguity

All conclusions from this dataset are associational. Even strong statistical signals do not establish causality. The listed genes may be downstream markers of a broader cellular transition, consequences of tissue composition changes, or bystander transcripts co-regulated with true drivers of RA. Functional experiments are required before any gene can be assigned a causal role.

---

# Final conclusion

The current transcriptomic data show a highly significant, coordinated downregulation of genes related to cell junctions/polarity/Wnt signaling, primary cilia/centrosomal/cytoskeletal organization, nuclear gene-expression regulation, and certain tissue-restricted markers. These findings are statistically robust but biologically should be considered **exploratory**. The most urgent priority is to resolve whether these signals reflect a genuine loss of resident synovial cell identity in RA or arise from tissue composition, contamination, treatment, and disease-stage differences.
